Family Planning

pregnant_woman Pregnancy & m.3243A>G

Understanding fertility, family planning and care through pregnancy, birth and recovery.

event Editorial update September 2026

Explanation

Important medical disclaimer

This page is written from a patient perspective, not by a doctor. Every effort has been made to base it on reputable medical research and clinical publications, but it should not be treated as medical advice, diagnosis, or treatment guidance.

Mitochondrial disease varies widely between individuals, and decisions about pregnancy planning, fertility choices, medications, delivery planning, and postnatal care should always be made with qualified healthcare professionals who know your medical history, symptoms, and current situation.

This site is intended to help people understand the condition, review the literature, and ask better questions, not replace professional care. If you have symptoms, concerns, or questions about your health, consult a qualified medical professional.

Thinking about pregnancy

Planning a family with m.3243A>G can bring several questions together: getting pregnant, what the mutation could mean for a child, and how pregnancy might affect your own health. Before trying to conceive, meeting your mitochondrial team, genetic counsellor and obstetric team gives you a chance to work through those questions and discuss the options that fit your priorities. Preconception counselling should bring together fertility concerns, reproductive genetics and maternal health. The mitochondrial, clinical genetics and obstetric teams can review the maternal phenotype, organ function and reproductive options in the context of the person’s priorities. ^{[1, 2, 3, 4]}

Successful pregnancies are reported, alongside risks that deserve careful planning. The aim of these conversations is to help you understand your own situation and make choices without pressure. You can take time, ask for explanations more than once, and involve a partner or someone you trust if you wish. Counselling should acknowledge both successful pregnancies and variable maternal and neonatal risks. It should be individualised and non-directive, allowing time to understand the evidence, uncertainties and available choices. ^{[1, 2]}

At a glance

Start with your questions

Getting pregnant, inheritance and your own health are separate questions. Discuss each as part of planning. Getting pregnant, inheritance and your own health are separate questions. Discuss each as part of planning. ^{[1, 2, 3, 4]}

Understand your choices

Genetic counselling can explain reproductive options and what testing can—and cannot—tell you. Genetic counselling can explain reproductive options and what testing can—and cannot—tell you. ^{[3, 4]}

Plan care around you

Pregnancy and birth plans should reflect your health, medicines and support needs. Pregnancy and birth plans should reflect your health, medicines and support needs. ^{[1, 2]}

Look beyond the birth

Plan for your recovery, feeding support and your baby’s follow-up as well as the birth. Plan for your recovery, feeding support and your baby’s follow-up as well as the birth. ^{[1, 2]}

Fertility and getting pregnant

Getting pregnant may be more difficult for some women, especially if periods are irregular and eggs are not released regularly. A small study of families with m.3243A>G reported infrequent periods and low reproductive hormone levels in two women. These reports suggest a possible concern for some people, but do not establish whether fertility difficulties are more common among carriers than in the general population. Subfertility may occur, particularly with ovulatory or endocrine dysfunction. In a small m.3243A>G family study, two female probands had oligomenorrhoea with low FSH and LH, interpreted as hypogonadotropic hypogonadism. The study did not measure time to pregnancy or the prevalence of infertility. ^{[16, 17]}

Having m.3243A>G does not mean you will necessarily have difficulty conceiving. A UK study of women with several inherited mitochondrial DNA changes found no clear difference in birth rates from the general population. However, it counted births rather than measuring how long it took to get pregnant, so it cannot rule out individual difficulties. A UK cohort of 154 women with inherited mtDNA variants found no statistically significant difference in live-birth rates from the general population. This mixed-genotype, birth-rate analysis does not establish normal fecundability in every m.3243A>G carrier or exclude a longer time to conception. ^[18]

If your periods are irregular, or you are worried about getting pregnant, raise this during pregnancy planning with your GP and specialist team. They can help decide whether hormone tests or a fertility assessment are appropriate. Fertility problems can have several causes and can affect either partner; they should not automatically be attributed to the mutation. Discuss menstrual irregularity or concerns about conception during preconception care. Assessment may include reproductive history, medication review, ovulation and hormone testing, and partner evaluation where relevant. Consider other causes and arrange fertility referral according to the clinical findings. ^{[17, 19]}

Inheritance and your family planning options

Mitochondrial DNA is usually passed through the egg. If you carry m.3243A>G, you may pass it on, but children in the same family can inherit very different amounts. This is one reason your own symptoms or a blood test result cannot give a certain prediction of a child’s health. Maternal transmission of m.3243A>G is influenced by heteroplasmy and germline segregation. Offspring mutation levels can differ substantially, and maternal blood heteroplasmy or phenotype alone cannot predict a child’s clinical outcome. ^{[3, 4, 5]}

The mix of changed and unchanged mitochondrial DNA can shift as eggs develop. This is known as the mitochondrial bottleneck. It helps explain why relatives can have different test results and symptoms, even though they share the same DNA change. The mitochondrial germline bottleneck can produce substantial shifts in heteroplasmy between generations. Clinical expression also depends on tissue distribution and other factors, so relatives carrying the same variant can have different manifestations. ^{[3, 5]}

Genetic counselling helps put your results into context and explain what each test could tell you. There is no single mutation percentage that reliably predicts a child’s future health. Reducing the chance of passing on a high mutation level and predicting how a child will be affected are related questions, but they are not the same. Variant-specific reproductive counselling must account for sampled tissue, heteroplasmy distribution and uncertain genotype–phenotype prediction. A reduction in transmission risk does not provide a deterministic prediction of clinical outcome. ^{[3, 4, 6, 7]}

Embryo and prenatal testing

There are testing options at different stages. Before pregnancy, IVF with embryo testing may allow selection of an embryo with a lower mutation level, which can reduce risk without guaranteeing a healthy child. Testing during pregnancy can measure the mutation level in a sample, but may not reliably predict how severely a child would be affected. A genetics team can explain these different limits before you decide whether testing would be helpful. Preimplantation genetic testing can support selection of embryos with lower heteroplasmy, subject to technical, reproductive and residual-risk limitations. During pregnancy, CVS or amniocentesis can measure sampled heteroplasmy, but prognostic interpretation remains variant-specific and uncertain. These limitations should be discussed before testing. ^{[3, 4]}

Egg donation

Using a screened donor egg avoids transmission of your own mitochondrial DNA through that egg. It involves donor conception and fertility treatment, with their own considerations and risks. Oocyte donation avoids transmission of the intending mother’s mtDNA through the donated oocyte; donor screening and reproductive treatment risks still apply. ^{[3, 4]}

Mitochondrial donation

Mitochondrial donation combines your nuclear genetic material with mitochondria from a donor egg. In the UK it is restricted to eligible cases at a licensed centre, with individual approval. Success and long-term outcomes remain uncertain. Maternal spindle or pronuclear transfer uses donor mitochondria while retaining parental nuclear DNA. UK access requires licensed treatment and case-specific HFEA approval; residual risks and long-term outcomes require counselling. ^[8]

Other routes and choices

Adoption, donor conception, natural conception or choosing not to have children are personal decisions. You can take time and seek support without having to justify your choice. Adoption, donor conception, natural conception or choosing not to have children are personal decisions. You can take time and seek support without having to justify your choice.

Care during pregnancy

Care during pregnancy needs to reflect the health you bring into it. Diabetes, heart or kidney involvement and seizures may each affect the monitoring you need. Agree who will coordinate your care and how to contact the team when something changes, so you are not left trying to join up separate pieces of advice. Pregnancy monitoring should reflect pre-existing endocrine, cardiac, renal and neurological involvement. Multidisciplinary coordination and clear escalation arrangements help integrate the individual care plan. ^{[1, 2]}

The table brings together checks to discuss with your team. It is a starting point for your own monitoring plan.

Monitoring to discuss with your pregnancy care team
What	Why	When
Blood pressure / pre-eclampsia screening	Blood pressure problems and pre-eclampsia have been reported. Ask whether preventive aspirin is appropriate for your personal risk; do not start it yourself. Assess hypertensive and pre-eclampsia risk and individual indications for aspirin prophylaxis. ^{[1, 2]}	As agreed with the obstetric team At the schedule specified in the obstetric plan ^{[1, 2]}
Blood glucose / HbA1c	Pregnancy can change blood sugar and insulin needs. Agree screening and treatment with the diabetes and obstetric teams. Assess pre-existing or gestational diabetes and adapt glycaemic treatment through pregnancy. ^{[1, 2]}	According to your diabetes plan Individualised glycaemic monitoring ^{[1, 2]}
Heart ultrasound Echocardiography	Heart assessment may be needed, especially with known heart involvement. Assess cardiac phenotype and haemodynamic tolerance. ^{[1, 2]}	Based on heart history and symptoms Individualised cardiac follow-up ^{[1, 2]}
Renal function	Kidney tests and urine protein may need monitoring. Review renal function and proteinuria. ^{[1, 2]}	Based on baseline results and symptoms Individualised renal follow-up ^{[1, 2]}
Lactate	Your team decides when lactate testing is useful, particularly if you are unwell. Lactate testing should have a clinical indication and be interpreted in context. ^{[1, 2]}	When clinically indicated When clinically indicated ^{[1, 2]}
Seizure activity	Report seizure changes; medicine review may be needed. Review seizure control and antiseizure therapy as pregnancy progresses. ^{[1, 2]}	Follow your seizure plan; report changes promptly Individual epilepsy review and escalation plan ^{[1, 2]}
Energy & fatigue	Discuss fatigue, reduced intake and the support you need. Assess fatigue, nutritional adequacy and functional support. ^{[1, 2]}	At reviews and if symptoms change At planned review and with clinical change ^{[1, 2]}

warning Discuss blood pressure early

Blood pressure problems, including pre-eclampsia, deserve early discussion with your maternity team. Small studies report different rates of complications, so one percentage cannot describe everyone’s risk. Ask what blood pressure monitoring you need and whether preventive aspirin is appropriate for you; do not start it without your team’s advice. Hypertensive complications and pre-eclampsia have been reported in m.3243A>G pregnancies, with estimates varying across small cohorts. Individualise surveillance and any aspirin prophylaxis to obstetric risk and current guidance. ^{[1, 2]}

Reviewing medicines and supplements

Diabetes treatment during pregnancy needs a separate plan. Your obstetric, diabetes and mitochondrial teams should agree your medicines and monitoring. Advice about metformin outside pregnancy should not be applied automatically. Coordinate pregnancy-specific glycaemic management. Non-pregnant mitochondrial diabetes recommendations cannot substitute for an obstetric risk–benefit assessment. ^{[1, 2, 12, 13]}

medication Plan medicine changes with your specialist

Review all medicines before conception. Valproate can seriously harm a developing baby, independently of mitochondrial disease. If you take it and might be pregnant, contact your specialist promptly; do not stop it yourself. Other medicines also need an individual review. Preconception medication reconciliation should address teratogenicity separately from genotype-specific mitochondrial toxicity. Valproate exposure requires prompt specialist review under applicable reproductive safety rules, without unsupervised withdrawal. ^{[9, 10, 11]}

Bring a full list of what you take, including supplements. These are useful points to cover during the review:

CoQ10: ask whether to continue it and what is known about pregnancy and breastfeeding safety. CoQ10: ask whether to continue it and what is known about pregnancy and breastfeeding safety. ^{[1, 2]}
Arginine and citrulline: review the reason for taking them and the limited pregnancy evidence. Arginine and citrulline: review the reason for taking them and the limited pregnancy evidence. ^{[1, 2]}
Seizure medicines: plan any changes with neurology; do not stop or adjust treatment yourself. Seizure medicines: plan any changes with neurology; do not stop or adjust treatment yourself. ^{[1, 2]}
Insulin: agree dose adjustments and monitoring with your diabetes team. Insulin: agree dose adjustments and monitoring with your diabetes team. ^{[1, 2]}
Folic acid: discuss starting before conception and the appropriate dose, especially with diabetes or seizure medicines. Folic acid: discuss starting before conception and the appropriate dose, especially with diabetes or seizure medicines. ^{[1, 2]}

The medication safety guide provides background for these conversations.

emergency

When to seek urgent medical care

Severe or new symptoms need prompt medical assessment. Use your personal emergency plan and share your diagnosis with the treating team. New neurological symptoms or severe systemic illness require prompt assessment and the individual emergency plan. ^{[12, 14]}

warning Seek urgent medical care now if:

New weakness, speech or vision changes, confusion, a severe new headache or a new seizure. Acute focal deficits, visual disturbance, encephalopathy, severe new headache or new seizures. ^{[12, 14]}
Persistent vomiting, inability to keep food or fluids down, or rapid deterioration. Persistent emesis, inability to maintain intake or rapid clinical deterioration. ^[12]
Chest pain, fainting or severe breathing difficulty. Chest pain, syncope or severe dyspnoea. ^{[12, 14]}
Severe abdominal pain or swelling with repeated vomiting. Severe abdominal pain or distension with recurrent emesis. ^{[12, 14, 15]}
Contact your maternity team promptly for new concerns or a change from your usual symptoms; follow the maternity warning signs in your birth plan. Use the individual obstetric escalation pathway for new symptoms or concerns. ^{[1, 2]}

Bring your personalised emergency letter, medicine and allergy list, and specialist contacts. Clinicians need to consider mitochondrial and other possible causes. Provide the individual emergency plan, medication reconciliation, allergies and specialist contacts; maintain a broad differential diagnosis. ^[12]

description Open Emergency Letter medication Medication Safety Guide clinical_notes Questions for your doctor

Planning the birth

Discuss the birth plan before labour begins, including pain relief, anaesthesia and what support you may need. Vaginal birth may be possible; the safest approach depends on your health and obstetric needs. Planning ahead also gives the team time to agree what to do if circumstances change. Develop an individual multidisciplinary delivery plan covering route of delivery, analgesia, anaesthesia and contingencies. Decisions should reflect maternal phenotype and obstetric indications rather than the genetic diagnosis alone. ^{[1, 2, 10, 12]}

Pain relief and anaesthesia

An anaesthetic appointment is a chance to discuss whether regional anaesthesia, such as an epidural, is suitable for you. Discuss the suitability of neuraxial or other regional anaesthesia as part of an individual anaesthetic assessment. ^{[1, 2, 10, 12]} If general anaesthesia is needed, the anaesthetist should make an individual plan for the medicines and monitoring involved. If general anaesthesia is required, individualise the drug regimen and perioperative monitoring. ^{[1, 2, 10, 12]}

Tell them about muscle weakness, any previous reactions to anaesthesia and other concerns you have. Discuss muscle weakness, previous anaesthetic reactions and other relevant risk factors. ^{[1, 2, 10, 12]} Make sure they also have your diagnosis and an up-to-date medication list. Provide the genetic diagnosis and current medication list for anaesthetic planning. ^{[1, 2, 10, 12]}

Support during labour

The labour plan should cover how food, blood sugar and fluid needs will be managed if you cannot eat. Plan nutritional, glycaemic and fluid management for any period of reduced oral intake during labour. ^{[1, 2, 10, 12]} The clinical team will choose fluids using your blood results, glucose levels and organ function. Fluid selection should account for laboratory results, glycaemia and organ function. ^{[1, 2, 10, 12]}

Agree which observations and blood tests are needed during labour. Specify appropriate observations and laboratory monitoring during labour. ^{[1, 2, 10, 12]} It also helps to discuss practical arrangements for treatment access and how extra help will be brought in if needed, Discuss practical treatment access and escalation arrangements, ^{[1, 2, 10, 12]} including how the team will support you if labour becomes exhausting. including support if maternal fatigue limits tolerance of labour. ^{[1, 2, 10, 12]}

Keep your personalised emergency letter in your hospital bag so the team can find the relevant information quickly. Keep the individual emergency plan readily available to the birth team. ^{[1, 2, 10, 12]}

If your baby arrives early

It is worth discussing the possibility of an early birth and what newborn care would be available at your hospital. Premature birth and neonatal problems have been reported, but rates differ greatly between studies and they are not inevitable. Your team can help you plan for the facilities appropriate to your pregnancy. Preterm birth and neonatal complications have been reported, with estimates varying across small observational cohorts. Discuss neonatal facilities and contingency planning according to individual maternal and fetal risk. ^{[1, 2]}

After birth: your baby and your recovery

Testing and follow-up for your baby

After birth, genetics and the children’s team can help you decide about testing and follow-up for your baby. The timing depends on the clinical situation and what a result would change. This is a conversation about the baby’s care as well as about obtaining a test result. Plan neonatal assessment and any mtDNA testing with clinical genetics and paediatrics. Timing should reflect clinical indication, the implications of the result and the follow-up it would inform. ^{[1, 2, 3, 4]}

Feeding support

If you would like to breastfeed, ask for support with a plan that works for you and your baby. This includes checking medicine compatibility and considering your own nutrition, fatigue, rest and practical help. Feeding is part of the postnatal plan, rather than something you have to work out alone once you are home. Individualise lactation support to medication compatibility, maternal nutritional status, fatigue and infant needs. Include feeding and practical support in postnatal planning. ^{[1, 2]}

Your recovery and follow-up

Practical help after birth can make room for your recovery as well as caring for your baby. Discuss who could help with meals, household tasks or appointments. Tell your team if fatigue, reduced intake or other symptoms are making recovery difficult, rather than assuming every change is simply part of having a newborn. Postnatal support should address maternal recovery, nutritional adequacy and functional limitations. Review new or worsening symptoms and arrange practical support with infant care and daily tasks as needed. ^{[1, 2]}

Before leaving hospital, agree your follow-up and who to contact with concerns. Diabetes treatment may need to change after birth, and monitoring should reflect your own heart, kidney and other health needs. Having those arrangements written down can make it easier to know what happens next. Arrange postpartum follow-up before discharge, including glycaemic reassessment, organ-specific surveillance and clear contact arrangements for new symptoms. ^{[1, 2]}

References

19 sources

Sources for the information on this page.

Hui L, Hayman P, Buckland A, Fahey MC, Mackey DA, Mallett AJ, Schweitzer DR, Stuart CP, Yau WY, Christodoulou J. (2025). Pregnancy in women with mitochondrial disease-A literature review and suggested guidance for preconception and pregnancy care. The Australian & New Zealand journal of obstetrics & gynaecology. Systematic reviewDOI Full text ↑ Back to text
Kuikka P, Nikkinen H, Majamaa K, Martikainen MH. (2026). Obstetric history of women with m.3243A>G: an observational cohort study. Journal of medical genetics. Research articleDOI Full text ↑ Back to text
Smeets HJM, Sallevelt SCEH, Herbert M. (2023). Reproductive options in mitochondrial disease. Handbook of clinical neurology. ReviewDOI ↑ Back to text
Lan X, Ao WL, Li J. (2024). Preimplantation genetic testing as a preventive strategy for the transmission of mitochondrial DNA disorders. Systems biology in reproductive medicine. ReviewDOI ↑ Back to text
Castelluccio N, Spath K, Li D, De Coo IFM, Butterworth L, Wells D, Mertes H, Poulton J, Heindryckx B. (2025). Genetic and reproductive strategies to prevent mitochondrial diseases. Human reproduction update. ReviewDOI ↑ Back to text
Pickett SJ, Grady JP, Ng YS, Gorman GS, Schaefer AM, Wilson IJ, Cordell HJ, Turnbull DM, Taylor RW, McFarland R. (2018). Phenotypic heterogeneity in m.3243A>G mitochondrial disease: The role of nuclear factors. Annals of clinical and translational neurology. Research articleDOI Full text ↑ Back to text
Grady JP, Pickett SJ, Ng YS, Alston CL, Blakely EL, Hardy SA, Feeney CL, Bright AA, Schaefer AM, Gorman GS, McNally RJ, Taylor RW, Turnbull DM, McFarland R. (2018). mtDNA heteroplasmy level and copy number indicate disease burden in m.3243A>G mitochondrial disease. EMBO molecular medicine. Research articleDOI Full text ↑ Back to text
Human Fertilisation and Embryology Authority (accessed 2026). Mitochondrial donation treatment . Official guidance↑ Back to text
Medicines and Healthcare products Regulatory Agency (accessed 2026). Valproate – reproductive risks . Official guidance↑ Back to text
De Vries MC, Brown DA, Allen ME, Bindoff L, Gorman GS, Karaa A, Keshavan N, Lamperti C, McFarland R, Ng YS, O'Callaghan M, Pitceathly RDS, Rahman S, Russel FGM, Varhaug KN, Schirris TJJ, Mancuso M. (2020). Safety of drug use in patients with a primary mitochondrial disease: An international Delphi-based consensus. Journal of inherited metabolic disease. Clinical guidanceDOI Full text ↑ Back to text
Mancuso M, Papadopoulou MT, Ng YS, Ardissone A, Bellusci M, Bertini E, Di Vito L, Evangelista T, Fons C, Hikmat O, Horvath R, Klopstock T, Kornblum C, Lamperti C, Licchetta L, Molnar MJ, Varhaug KN, O'Callaghan M, Pressler RM, Schiff M, Servidei S, Szabo N, Gorman GS, Cross JH, Rahman S. (2024). Management of seizures in patients with primary mitochondrial diseases: consensus statement from the InterERNs Mitochondrial Working Group. European journal of neurology. Clinical guidanceDOI Full text ↑ Back to text
Sue CM, Balasubramaniam S, Bratkovic D, Bonifant C, Christodoulou J, Coman D, Crawley K, Edema-Hildebrand F, Ellaway C, Ghaoui R, Kava M, Kearns LS, Lee J, Liang C, Mackey DA, Murray S, Needham M, Rius R, Russell J, Smith NJC, Thyagarajan D, Wools C. (2022). Patient care standards for primary mitochondrial disease in Australia: an Australian adaptation of the Mitochondrial Medicine Society recommendations. Internal medicine journal. Clinical guidanceDOI Full text ↑ Back to text
Chaudhry A, Thompson DM, Chanoine JP. (2026). Diabetes management in maternally inherited diabetes and deafness (MIDD): A review and a proposed treatment algorithm. Diabetes, obesity & metabolism. ReviewDOI Full text ↑ Back to text
Mancuso M, Bellusci M, Carelli V, de Coo I, Diodato D, Distelmaier F, Hikmat O, Hirano M, Horvath R, Karaa A, Klopstock T, Koenig MK, Kornblum C, La Morgia C, Lopriore P, Martikainen MH, McFarland R, Musumeci O, Pitceathly RDS, Primiano G, Rahman S, Scaglia F, Schaefer A, Schiff M, Semmler L, Lamperti C, Servidei S. (2026). Diagnostic Criteria and Management of MELAS and Stroke-Like Episodes: Consensus-Based Statements. European journal of neurology. Clinical guidanceDOI Full text ↑ Back to text
de Laat P, Zweers HE, Knuijt S, Smeitink JA, Wanten GJ, Janssen MC. (2015). Dysphagia, malnutrition and gastrointestinal problems in patients with mitochondrial disease caused by the m3243A>G mutation. The Netherlands journal of medicine. Research article↑ Back to text
Zhou MC, Min R, Ji JJ, Zhang S, Tong AL, Xu JP, Li ZY, Zhang HB, Li YX. (2015). Analysis of association among clinical features and shorter leukocyte telomere length in mitochondrial diabetes with m.3243A>G mitochondrial DNA mutation. BMC medical genetics. Observational studyDOI Full text ↑ Back to text
NHS (accessed 2026). Irregular periods . Official guidance↑ Back to text
Gorman GS, Grady JP, Turnbull DM. (2015). Mitochondrial donation--how many women could benefit? The New England journal of medicine. Observational studyDOI Full text ↑ Back to text
NHS (accessed 2026). Diagnosis of infertility . Official guidance↑ Back to text

Browse the research library for papers grouped by topic.

Conditions

Care

Tools & Resources

About

pregnant_woman Pregnancy & m.3243A>G

Thinking about pregnancy

Fertility and getting pregnant

Inheritance and your family planning options

Embryo and prenatal testing

Egg donation

Mitochondrial donation

Other routes and choices

Care during pregnancy

Reviewing medicines and supplements

When to seek urgent medical care

Planning the birth

Pain relief and anaesthesia

Support during labour

If your baby arrives early

After birth: your baby and your recovery

Testing and follow-up for your baby

Feeding support

Your recovery and follow-up

References

Thinking about pregnancy

Fertility and getting pregnant

Inheritance and your family planning options

Embryo and prenatal testing

Egg donation

Mitochondrial donation

Other routes and choices

Care during pregnancy

Reviewing medicines and supplements

When to seek urgent medical care

Planning the birth

Pain relief and anaesthesia

Support during labour

If your baby arrives early

After birth: your baby and your recovery

Testing and follow-up for your baby

Feeding support

Your recovery and follow-up

References

Related pages